Topical finasteride — applied directly to the scalp as a solution or spray rather than taken as an oral tablet — has emerged as a meaningful alternative for patients who want the benefits of finasteride with lower systemic exposure and reduced risk of systemic side effects.
The rationale for topical application is pharmacokinetic. Oral finasteride achieves its DHT-reducing effect primarily in the scalp but does so by achieving systemic drug levels throughout the body, which may contribute to its side effect profile. Topical formulations are designed to achieve high drug concentrations in the scalp tissue while minimising systemic absorption — the drug acts locally where it is needed without being distributed systemically.
Clinical studies comparing topical to oral finasteride show that topical formulations achieve comparable reductions in scalp DHT levels to oral finasteride, with significantly lower serum drug levels. Early evidence on side effect rates suggests that systemic side effects are less common with topical formulations, though the evidence base is smaller than for oral finasteride, which has been studied for thirty years.
Topical finasteride is typically available at a concentration of 0.25% to 1%, applied once daily to the affected scalp areas. It is available from specialist pharmacies and hair loss clinics as a prescription product. Some formulations combine finasteride with minoxidil in a single topical preparation, simplifying the treatment regimen.
For patients who are interested in finasteride but concerned about systemic side effects, topical finasteride is a reasonable first approach — with the understanding that oral finasteride may still be considered if topical formulations are not providing sufficient effect.
Related reading
